Oropharyngeal Administration of Colostrum Increases Salivary Secretory IgA Levels in Very Low-Birth-Weight Infants

Kristen M. Glass; Coleen P. Greecher; Kim K. Doheny

doi:10.1055/s-0037-1603655

American Journal of Perinatology, Table of Contents

Am J Perinatol 2017; 34(14): 1389-1395
DOI: 10.1055/s-0037-1603655

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Oropharyngeal Administration of Colostrum Increases Salivary Secretory IgA Levels in Very Low-Birth-Weight Infants

Kristen M. Glass

¹Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania

,

Coleen P. Greecher

²Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania

,

Kim K. Doheny

¹Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania

³Department of Neural and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania

› Author Affiliations

Abstract

Aim Oropharyngeal administration of colostrum (OAC) has been proposed to provide mother's early milk to very low-birth-weight (VLBW) infants in the first few days of life. The aim of this study was to test the hypothesis that OAC would increase salivary secretory IgA (SsIgA).

Patients and Methods Overall, 30 VLBW infants randomized to receive OAC or sterile water had salivary sampling for SsIgA on the day of life (DOL) 2, 7, and 14. The incidence of late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) was determined prospectively. Within and between-group comparisons were made by paired and independent samples t-tests.

Results Baseline characteristics were similar between groups. SsIgA was higher in OAC versus the control group (p < 0.05) on DOL 7, but not subsequently on DOL 14. There was no difference in LOS or NEC.

Conclusion OAC increased SsIgA at DOL 7. A large, multicenter trial is needed to determine if OAC decreases LOS or NEC in VLBW infants.

Keywords

colostrum - salivary secretory IgA - VLBW infant - infection

Full Text

References

References
1 Stoll BJ, Hansen N, Fanaroff AA. , et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110 (2 Pt 1): 285-291
2 Furman L, Taylor G, Minich N, Hack M. The effect of maternal milk on neonatal morbidity of very low-birth-weight infants. Arch Pediatr Adolesc Med 2003; 157 (01) 66-71
3 Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999; 103 (6 Pt 1): 1150-1157
4 Buescher ES. Anti-inflammatory characteristics of human milk: how, where, why. Adv Exp Med Biol 2001; 501: 207-222
5 Garofalo RP, Goldman AS. Cytokines, chemokines, and colony-stimulating factors in human milk: the 1997 update. Biol Neonate 1998; 74 (02) 134-142
6 Araújo ED, Gonçalves AK, Cornetta MdaC. , et al. Evaluation of the secretory immunoglobulin A levels in the colostrum and milk of mothers of term and pre-term newborns. Braz J Infect Dis 2005; 9 (05) 357-362
7 Koenig A, de Albuquerque Diniz EM, Barbosa SF, Vaz FA. Immunologic factors in human milk: the effects of gestational age and pasteurization. J Hum Lact 2005; 21 (04) 439-443
8 Westerbeek EA, van den Berg A, Lafeber HN, Knol J, Fetter WP, van Elburg RM. The intestinal bacterial colonisation in preterm infants: a review of the literature. Clin Nutr 2006; 25 (03) 361-368
9 Rodriguez NA, Meier PP, Groer MW, Zeller JM. Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives. J Perinatol 2009; 29 (01) 1-7
10 Eid P, Meritet JF, Maury C, Lasfar A, Weill D, Tovey MG. Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. J Interferon Cytokine Res 1999; 19 (02) 157-169
11 Lecciones JA, Abejar NH, Dimaano EE. , et al. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-alpha-n1 (Ins) in pediatric patients with measles. J Interferon Cytokine Res 1998; 18 (09) 647-652
12 Tovey MG, Meritet JF, Guymarho J, Maury C. Mucosal cytokine therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 1999; 19 (08) 911-921
13 Bocci V, von Bremen K, Corradeschi F, Luzzi E, Paulesu L. What is the role of cytokines in human colostrum?. J Biol Regul Homeost Agents 1991; 5 (04) 121-124
14 Field CJ. The immunological components of human milk and their effect on immune development in infants. J Nutr 2005; 135 (01) 1-4
15 Ogawa J, Sasahara A, Yoshida T. , et al. Role of transforming growth factor-beta in breast milk for initiation of IgA production in newborn infants. Early Hum Dev 2004; 77 (1-2): 67-75
16 Goldblum RM, Schanler RJ, Garza C, Goldman AS. Human milk feeding enhances the urinary excretion of immunologic factors in low birth weight infants. Pediatr Res 1989; 25 (02) 184-188
17 Schanler RJ, Goldblum RM, Garza C, Goldman AS. Enhanced fecal excretion of selected immune factors in very low birth weight infants fed fortified human milk. Pediatr Res 1986; 20 (08) 711-715
18 Neu M, Goldstein M, Gao D, Laudenslager ML. Salivary cortisol in preterm infants: Validation of a simple method for collecting saliva for cortisol determination. Early Hum Dev 2007; 83 (01) 47-54
19 Lee J, Kim HS, Jung YH. , et al. Oropharyngeal colostrum administration in extremely premature infants: an RCT. Pediatrics 2015; 135 (02) e357-e366
20 Rodriguez NA, Meier PP, Groer MW, Zeller JM, Engstrom JL, Fogg L. A pilot study to determine the safety and feasibility of oropharyngeal administration of own mother's colostrum to extremely low-birth-weight infants. Adv Neonatal Care 2010; 10 (04) 206-212
21 Montgomery D, Baer V, Lambert D, Christensen R. Oropharyngeal administration of colostrum to very low birth weight infants: results of a feasibility trial. Neonatal Intensive Care 2010; 23: 27-29
22 Gephart SM, Weller M. Colostrum as oral immune therapy to promote neonatal health. Adv Neonatal Care 2014; 14 (01) 44-51
23 Spencer J, Macdonald TT. Ontogeny of human mucosal immunity. In: Macdonald TT. , ed. Ontogeny of the Immune System of the Gut. Boca Raton, FL: CRC Press; 1990: 23-50
24 Stoll BJ, Lee FK, Hale E. , et al. Immunoglobulin secretion by the normal and the infected newborn infant. J Pediatr 1993; 122 (5 Pt 1): 780-786
25 Ng PC, Li K, Wong RP. , et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed 2003; 88 (03) F209-F213
26 Kadaoui KA, Corthésy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol 2007; 179 (11) 7751-7757
27 Corthésy B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 2013; 12 (06) 661-665
28 Rodriguez NA, Groer MW, Zeller JM. A randomized, controlled trial of the oropharyngeal administration of mother's colostrum to extremely low birth weight infants in the first few days of life. Neonatal Intensive Care 2011; 24 (04) 31-35
29 Seigel JK, Smith PB, Ashley PL. , et al. Early administration of oropharyngeal colostrum to extremely low birth weight infants. Breastfeed Med 2013; 8 (06) 491-495
30 Rodriguez NA, Vento M, Claud EC, Wang CE, Caplan MS. Oropharyngeal administration of mother's colostrum, health outcomes of premature infants: study protocol for a randomized controlled trial. Trials 2015; 16 (01) 453 . Doi: 10.1186/s13063-015-0969-6